Insight Molecular Diagnostics Inc. (IMDX) - Dilution Analysis

10-K filing | 30.5M shares outstanding

10-Q filing | 28.6M shares outstanding

10-Q filing | 28.6M shares outstanding

S-1 filing: This prospectus relates to the resale by the selling stockholders named in this prospectus from time to time of up to 10,606,632 shares of our common stock.

10-K filing | 28.6M shares outstanding

8-K filing: Oncocyte Corporation entered into a securities purchase agreement for a private placement of common stock and pre-funded warrants, and a registered direct offering of common stock. ($29.1M proceeds)

10-Q filing | 16.8M shares outstanding

S-3/A filing: Resale of 3,461,138 shares of common stock by selling stockholders.

S-3 filing: This S-3 filing registers the resale of up to 3,461,138 shares of common stock by selling stockholders, which were previously issued pursuant to a securities purchase agreement dated October 2, 2024.

8-K filing: Oncocyte Corporation entered into a securities purchase agreement for the issuance and sale of 3,461,138 shares of common stock at a price of $2.948 per share in a private placement, with gross proceeds expected to be approximately $10.2 million. ($10.2M proceeds)

10-Q filing | 12.9M shares outstanding

S-3 filing: The filing is an S-3 form indicating the company may offer and sell shares of its common stock, preferred stock, warrants, units consisting of a combination of the foregoing securities or any other combination of the foregoing, either individually or as a combination of one or more of these securities, having an aggregate initial offering price of up to $100,000,000.

S-3/A filing: This S-3/A filing registers for resale up to 5,419,788 shares of common stock by selling stockholders, comprised of PIPE Shares and Pre-Funded Warrant Shares. The company will not receive any proceeds from the sale of these shares, but may receive proceeds from the exercise of Pre-Funded Warrants.

10-Q filing | 13.4M shares outstanding

S-3 filing: The filing is an S-3 registration statement for the resale of up to 5,419,788 shares of common stock by selling stockholders, including PIPE Shares and Pre-Funded Warrant Shares. The company will not receive any proceeds from the sale of these shares, but may receive proceeds from the exercise of the Pre-Funded Warrants.

10-K filing | 7.7M shares outstanding

8-K filing: Oncocyte Corporation entered into a securities purchase agreement for the issuance and sale of 5,077,387 common shares and pre-funded warrants to purchase up to 342,888 common shares in a private placement, expected to close on or about April 15, 2024. ($15.8M proceeds)

10-Q filing | 8.3M shares outstanding

10-Q filing | 8.2M shares outstanding

8-K filing: Stock split 1-for-20 | Outstanding: 164,821,077 → 8,241,053

10-Q filing | 164.8M shares outstanding

10-K filing | 119.3M shares outstanding

8-K filing: Oncocyte Corporation entered into a securities purchase agreement for the sale and issuance of 45,494,198 shares of common stock at $0.30168 to non-insiders and $0.35440 to insiders in a registered direct offering. ($0.0M proceeds)

8-K filing: On February 16, 2023, Oncocyte completed the Razor Sale Transaction, selling approximately 70% of the issued and outstanding equity interests of Razor to Dragon Scientific, LLC.

8-K filing: Oncocyte Corporation amended its Stock Purchase Agreement with Dragon Scientific, LLC and Razor Genomics Inc. to extend the Outside Date for the closing of the sale of Razor Genomics Inc. shares to February 15, 2023.

8-K filing: Oncocyte Corporation entered into a Stock Purchase Agreement with Dragon Scientific, LLC, to sell 3,188,181 shares of common stock of Razor Genomics Inc., which constitutes approximately 70% of the issued and outstanding equity interests of Razor.

10-Q filing | 118.6M shares outstanding

10-Q filing | 113.0M shares outstanding

10-Q filing | 118.5M shares outstanding

8-K filing: Oncocyte Corporation completed a public offering of 26,266,417 shares of common stock and warrants, with the underwriters exercising their option to purchase 3,939,962 warrants, resulting in net proceeds of approximately $32.9 million for the company. ($35.03M proceeds)

8-K filing: Oncocyte Corporation entered into a securities purchase agreement with institutional accredited investors for a registered direct offering of Series A Convertible Preferred Stock, convertible into 7,689,542 shares of common stock, for gross proceeds of $10,000,000. ($10.0M proceeds)

10-K filing | 92.2M shares outstanding

10-Q filing | 92.2M shares outstanding

10-Q filing | 91.6M shares outstanding

S-3 filing: This S-3 filing, dated July 14, 2021, relates to the potential resale of up to 9,436,465 shares of Oncocyte Corporation's common stock by selling shareholders.

S-3 filing: The company may offer and sell up to $240 million in the aggregate of common stock, preferred stock, warrants, units or any combination of the foregoing.

10-Q filing | 69.1M shares outstanding

10-K filing | 57.0M shares outstanding

8-K filing: OncoCyte Corporation entered into a Purchase Agreement with Piper Sandler & Co. to issue and sell 7,780,000 shares of common stock at a public offering price of $4.50 per share, with an option for the underwriters to purchase up to an additional 1,167,000 shares to cover over-allotments, closing expected on or about February 9, 2021. ($35.01M proceeds)

8-K filing: OncoCyte Corporation entered into a Merger Agreement with Chronix Biomedical, where OncoCyte will deliver $2.675 million in cash and $1.5 million of OncoCyte common stock (approximately 295,000 shares) as closing consideration.

8-K filing: On January 20, 2021, the company entered into Subscription Agreements for a registered direct offering of 7,301,410 shares of common stock at $3.424 per share, for gross proceeds of $25,000,027.84. ($25.0M proceeds)

10-Q filing | 67.3M shares outstanding

S-3 filing: Registration of resale of common stock previously issued in connection with the acquisition of Insight Genetics, Inc.

10-Q filing | 67.2M shares outstanding

10-Q filing | 62.5M shares outstanding

8-K filing: The company entered into subscription agreements for a registered direct offering of up to 4,733,700 shares of common stock at $2.27 per share, with the sale expected to close during the week of April 27, 2020. ($10.75M proceeds)

10-K filing | 40.7M shares outstanding

8-K filing: OncoCyte Corporation entered into a Merger Agreement with Insight Genetics, involving cash and stock consideration, earnout provisions, and potential milestone payments.

8-K filing: On January 2, 2020, the company entered into Subscription Agreements for a registered direct offering of 3,523,776 shares of common stock at $2.156 per share, for gross proceeds of approximately $7.6 million, with the sale expected to close during the week of January 6, 2020. ($7.6M proceeds)